This is a study evaluating the efficacy, safety, and pharmacokinetics of MK-1084 in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation and MK-1084 plus pembrolizumab in participants with first line (1L) non-small cell lung cancer (NSCLSC) with identified KRASG12C mutation.
Ontario
Hamilton Health Sciences, Juravinski Cancer Centre
Princess Margaret Cancer Centre, Toronto
| ClinicalTrials.gov Identifier: |
NCT04931654 |
This study is currently active and recruiting participants
This study (the SAVANNAH study) will investigate the efficacy of osimertinib in combination with savolitinib in patients with EGFRm+ and MET+, locally advanced or metastatic NSCLC who have progressed following treatment with osimertinib
Alberta
Calgary
Edmonton
Ontario
Newmarket
North York
Toronto
| ClinicalTrials.gov Identifier: |
NCT053640734931654 |
This study is currently active and recruiting participants
| ClinicalTrials.gov Identifier: |
NCT05364073 |
This study is currently recruiting participants.
This is a Phase 1b, open-label, multi-center, dose-escalation and dose expansion study designed to evaluate the safety, pharmacokinetics (PK), and preliminary antitumor activity of furmonertinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating, including uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) mutations. Patients will be enrolled into one of 2 stages: Stage 1 (Dose Escalation and Backfill Cohorts) and Stage 2 (Dose Expansion).
Alberta
Edmonton
Ontario
Toronto
| ClinicalTrials.gov Identifier: |
NCT05241873 |
This study is currently active and recruiting participants
This is a Phase 1/2, open-label first-in-human study of the safety, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLU-451 monotherapy and BLU-451 in combination with platinum-based chemotherapy (carboplatin and pemetrexed). All participants will receive BLU-451 on a 21-day treatment cycle.
Ontario
Princess Margaret Cancer Centre
| ClinicalTrials.gov Identifier: |
NCT04931654 |
This study is currently active and recruiting participants
This study will compare the clinical activity of novel regimens (in combination or as single agents) to SoC in participants with relapsed/refractory advanced NSCLC. The study will be conducted in two parts. Part 1 is an open-label, optional, non-randomized part based on safety and pharmacokinetics/pharmacodynamics (PK/PD) evaluation intended to generate additional data to qualify novel regimens for the randomized study. Part 2 is a randomized, Phase II open-label part comparing the efficacy and safety of these novel regimens with SoC. Drug name mentioned as GSK4428859A and EOS884448 are interchangeable for the same compound and will be referred to as GSK4428859A/EOS884448.
Alberta
Edmonton, Alberta, Canada, T6G 1Z2
Contact: US GSK Clinical Trials Call Center 877-379-3718
[email protected]
Contact: EU GSK Clinical Trials Call Centre +44 (0) 20 8990 4466
[email protected]
Principal Investigator: Quincy Chu
Ontario
Brampton, Ontario, Canada, L6R 3J7
Contact: US GSK Clinical Trials Call Center 877-379-3718
[email protected]
Contact: EU GSK Clinical Trials Call Centre +44 (0) 20 8990 4466
[email protected]
Principal Investigator: Parneet Cheema
Toronto, Ontario, Canada, M5G 2M9
Contact: US GSK Clinical Trials Call Center 877-379-3718
[email protected]
Contact: EU GSK Clinical Trials Call Centre +44 (0) 20 8990 4466
[email protected]
Principal Investigator: Adrian Sacher
| ClinicalTrials.gov Identifier: |
NCT04335292 |
This study is currently recruiting participants.
This phase II single-armed study will examine the clinical utility of retreating patients with osimertinib, in the third-line, following first-line treatment with osimertinib and second-line treatment with platinum and pemetrexed chemotherapy. The current standard of care for first-line Epidermal Growth Factor Receptor (EGFR) mutated Advanced Non-Small Cell Lung Cancer (aNSCLC) is osimertinib, followed by cytotoxic chemotherapy.
The repeat of osimertinib following previous treatment failure is investigational, although supported by scientific rationale. The dosing and scheduling of osimertinib follows its use in approved settings. The investigators examine its tolerability and efficacy in this setting to ensure osimertinib is a safe third-line option for patients with Epidermal Growth Factor Receptor mutated (EGFR+) Advanced Non-Small Cell Lung Cancer(aNSCLC).
British Colombia
Vancouver
Ontario
Brampton
Hamilton
Kitchener
London
Oshawa
Ottawa
Toronto
| ClinicalTrials.gov Identifier: |
NCT05261399 |
This study is currently recruiting participants.
Clinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on treatment with Osimertinib.
Ontario
Toronto
Quebec
Montreal
| ClinicalTrials.gov Identifier: |
NCT04862780 |
This study is currently recruiting participants.
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-945, a selective EGFR inhibitor, as monotherapy or in combination with osimertinib.
Ontario
Princess Margaret Cancer Centre, Toronto
| ClinicalTrials.gov Identifier: |
NCT05388669 |
This study is currently recruiting participants.
The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), for subcutaneous administration. This formulation has the potential to enhance both the patient and physician experience with amivantamab by providing easier and accelerated administration.
Ontario
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada, K1H 8L6
Princess Margaret Hospital, Toronto, Ontario, Canada, M5G 1Z5
| ClinicalTrials.gov Identifier: |
NCT04656652 |
This study is active but not currently recruiting.
This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations.
Alberta
Edmonton
Ontario
University Health Network, Toronto
Sunnybrtook Health Sciences Centre, Toronto
Quebec
Montreal
| ClinicalTrials.gov Identifier: |
NCT02785952 |
This study is active but not currently recruiting.
This randomized phase III trial compares nivolumab with ipilimumab and nivolumab alone in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a "non-match" sub-study that includes all screened patients not eligible for a biomarker-driven sub-study. Monoclonal antibodies, such as nivolumab and ipilimumab, may be able to shrink tumours. It is not yet known whether nivolumab works better with or without ipilimumab in treating patients with squamous cell lung cancer.
Ontario
University Health Network-Princess Margaret Hospital, Toronto
Saskatchewan
Allan Blair Cancer Centre, Regina
Saskatoon Cancer Centre, Saskatoon
| ClinicalTrials.gov Identifier: |
NCT03539536 |
This study is active but not currently recruiting.
This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2).
Alberta
Cross Cancer Institute / ID# 204540, Edmonton
Ontario
The Ottawa Hospital / ID# 205579, Ottawa
Princess Margaret Cancer Centre, Toronto
Quebec
CISSS de la Monteregie / ID# 211356, Greenfield Park
| ClinicalTrials.gov Identifier: |
NCT03334617 |
This study is active but not currently recruiting.
This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.
Alberta
Edmonton
Ontario
Brampton
Ottawa
Toronto
Quebec
Montreal